Trial Profile
Phase IIa of Tocilizumab In the Treatment of Polymyalgia Rheumatica
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Polymyalgia rheumatica
- Focus Adverse reactions; Therapeutic Use
- 09 May 2016 Status changed from active, no longer recruiting to completed, according to results published in the Arthritis and Rheumatology.
- 09 May 2016 Results published in the Arthritis and Rheumatology
- 19 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.